Poltiss sp. z o.o.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2015-09-10
Share capital
10,700.00 PLN
Activity description

Poltiss is a company that develops PhotoBioCure™ technology, which utilizes biopolymers that transform from a sticky liquid to flexible solids under UV radiation to create customized, biodegradable implants for tissue defects. Their biomaterials are designed for minimally invasive surgical procedures, eliminating the need for sutures and facilitating tissue regeneration. Founded in 2015, Poltiss focuses on improving the comfort of patients and surgeons through their programmable biopolymers.

Registered address
al. Wojska Polskiego 150/1, 71-324 Szczecin, Poland
Email
Electronic delivery address
AE:PL-51307-78150-UTWDB-25

Financials

Revenue history (in k)

Filing timeliness

3 of 6 financial statements were filed late (the longest delay 77 days for 2021).

  • 202520/07/2026
  • 202409/06/2025
  • 202312/09/2024
  • 202212/06/2023
  • 202130/09/2022
  • 202023/09/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Division · Scientific research and development1,552 / 1,943
Top 80%
City · Szczecin4,070 / 4,611
Top 88%
Voivodeship · Zachodniopomorskie9,465 / 10,451
Top 91%
Country · Poland269,443 / 297,266
Top 91%

Results vs industry

Revenue
This companyUSD 3.84kMedianUSD 56.72kAverageUSD 2.72m
Net profit
This companyUSD -9.00kMedianUSD -1.27kAverageUSD -93.01k
Operating costs
This companyUSD 4.23kMedianUSD 66.48kAverageUSD 2.68m
Assets
This companyUSD 9.12kMedianUSD 134.71kAverageUSD 3.04m

Authorized Representatives

Mirosława El Fray – President of the Management Board

Manner of representation

If one person is appointed to the management board, the company shall be represented by one member of the management board independently; if more than one person is appointed to the management board, the company shall be represented by two members of the management board acting jointly or by a member of the management board jointly with a commercial proxy.

Ownership

OwnerSharesShare valueStake
54$729.3425.2336%
95$1,283.0944.3925%
51$688.8223.8318%
Others
14$189.096.5421%

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2019-03-01.

  • mBank
    08 1140 2004 0000 3602 8076 0508
  • mBank
    90 1140 2004 0000 3202 7567 5264
  • mBank
    21 1140 2004 0000 3602 8076 0468

Debt

No entries in the National Debtors Register (KRZ).

Public aid

7 public aid cases recorded, with a total value of $646,802.

PurposeGross amount
De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)
$2,142
Aid for research and development projects: industrial research
$112.8K
Aid for research and development projects: experimental development
$38,047

European Funds

ProjectEU co-financing
Development of new functionalities for PhotoBioCure technology and clinical testing of its safety and efficacy.
$165.5K

Competitors

Name
Stenocoat sp. z o.o.
Bonereg sp. z o.o.
Arthec S.A.
Thesybin Labs P.S.A.
Oncotherics Poland S.A.
Fusiomica sp. z o.o.
Centrum Inżynierii Niekonwencjonalnej sp. z o.o.
Spinbionic sp. z o.o.
Refoldit sp. z o.o.
BIO Science Centrum Badań Doświadczalnych sp. z o.o.

Change history

DateEvent
2023-12-20Share capital increase
2021-10-04Address change
2021-06-29Share capital increase
2021-05-31Share capital increase
2018-07-30Address change

FAQ

Last updated: 2026-07-20